trending Market Intelligence /marketintelligence/en/news-insights/trending/b664Y-dy7fkAt9bBPkIDZQ2 content esgSubNav
In This List

Sesen Bio begins US FDA application process for bladder cancer drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Sesen Bio begins US FDA application process for bladder cancer drug

Sesen Bio Inc. has initiated the submission of bladder cancer drug Vicinum to the U.S. Food and Drug Administration for approval.

The Cambridge, Mass.-based company expects to complete the rolling submissions process by 2020. Sesen plans to request a priority review if the FDA accepts the application.

Vicinum, which treats high-grade, non-muscle-invasive bladder cancer, was granted fast-track designation from the U.S. regulator in 2018. The drug removed detectable cancer in 39% to 80% of patients in a late-stage clinical trial, according to results issued in May 2018.